ES2362062B1 - NEW CONJUGATES AND COMPOSITIONS FOR IMMUNOTHERAPY AND ANTI-TUMORAL TREATMENT. - Google Patents
NEW CONJUGATES AND COMPOSITIONS FOR IMMUNOTHERAPY AND ANTI-TUMORAL TREATMENT. Download PDFInfo
- Publication number
- ES2362062B1 ES2362062B1 ES200931158A ES200931158A ES2362062B1 ES 2362062 B1 ES2362062 B1 ES 2362062B1 ES 200931158 A ES200931158 A ES 200931158A ES 200931158 A ES200931158 A ES 200931158A ES 2362062 B1 ES2362062 B1 ES 2362062B1
- Authority
- ES
- Spain
- Prior art keywords
- compositions
- immunotherapy
- immune response
- new conjugates
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn - After Issue
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 102000018619 Apolipoproteins A Human genes 0.000 abstract 1
- 108010027004 Apolipoproteins A Proteins 0.000 abstract 1
- 102000003812 Interleukin-15 Human genes 0.000 abstract 1
- 108090000172 Interleukin-15 Proteins 0.000 abstract 1
- 102000004556 Interleukin-15 Receptors Human genes 0.000 abstract 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 abstract 1
- 230000033289 adaptive immune response Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 230000015788 innate immune response Effects 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A61K47/48269—
-
- A61K47/48276—
-
- A61K47/48346—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se relaciona con composiciones que presentan capacidad de promover tanto la respuesta inmune innata como de la respuesta inmune adaptativa en un sujeto basadas en el uso conjunto de ApoA, interleuquina 15 y del dominio sushi de la cadena alfa del receptor de IL 15, así como al uso de estas composiciones para estimular la respuesta inmune en un paciente y en métodos terapéuticos para el tratamiento de enfermedades infecciosas y neoplásicas.The present invention relates to compositions that have the ability to promote both the innate immune response and the adaptive immune response in a subject based on the joint use of ApoA, interleukin 15 and the sushi domain of the alpha chain of the IL 15 receptor, as well as the use of these compositions to stimulate the immune response in a patient and in therapeutic methods for the treatment of infectious and neoplastic diseases.
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200931158A ES2362062B1 (en) | 2009-12-11 | 2009-12-11 | NEW CONJUGATES AND COMPOSITIONS FOR IMMUNOTHERAPY AND ANTI-TUMORAL TREATMENT. |
BR112012013868A BR112012013868A8 (en) | 2009-12-11 | 2010-12-10 | composition, fusion protein, polynucleotide, gene vector or construct, host cell, pharmaceutical composition, in vitro method and use of a composition. |
US13/514,855 US8771664B2 (en) | 2009-12-11 | 2010-12-10 | Compositions comprising apolipoprotein A polypeptide and interleukin 15, and methods of treatment using the same |
MX2012006691A MX2012006691A (en) | 2009-12-11 | 2010-12-10 | Conjugates and compositions for immunotherapy and anti-tumor treatment. |
PCT/ES2010/070818 WO2011070214A2 (en) | 2009-12-11 | 2010-12-10 | Novel conjugates and compositions for immunotherapy and antineoplastic treatment |
JP2012542587A JP5784626B2 (en) | 2009-12-11 | 2010-12-10 | Novel conjugates and compositions for immunotherapy and anti-tumor therapy |
ES10814739.8T ES2463016T3 (en) | 2009-12-11 | 2010-12-10 | Conjugates and compositions for immunotherapy and anti-tumor treatment |
AU2010329805A AU2010329805B2 (en) | 2009-12-11 | 2010-12-10 | New conjugates and compositions for immunotherapy and anti-tumoral treatment |
CA2783876A CA2783876C (en) | 2009-12-11 | 2010-12-10 | New conjugates and compositions for immunotherapy and antitumoral treatment |
EP10814739.8A EP2511294B1 (en) | 2009-12-11 | 2010-12-10 | Conjugates and compositions for immunotherapy and anti-tumoral treatment |
RU2012129208/10A RU2597989C2 (en) | 2009-12-11 | 2010-12-10 | Conjugates and compositions for immunotherapy and anticancer treatment |
CN201080061939.9A CN102753574B (en) | 2009-12-11 | 2010-12-10 | Novel conjugates and compositions for immunotherapy and antineoplastic treatment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200931158A ES2362062B1 (en) | 2009-12-11 | 2009-12-11 | NEW CONJUGATES AND COMPOSITIONS FOR IMMUNOTHERAPY AND ANTI-TUMORAL TREATMENT. |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2362062A1 ES2362062A1 (en) | 2011-06-28 |
ES2362062B1 true ES2362062B1 (en) | 2012-05-09 |
Family
ID=44144475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES200931158A Withdrawn - After Issue ES2362062B1 (en) | 2009-12-11 | 2009-12-11 | NEW CONJUGATES AND COMPOSITIONS FOR IMMUNOTHERAPY AND ANTI-TUMORAL TREATMENT. |
Country Status (1)
Country | Link |
---|---|
ES (1) | ES2362062B1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8097283B2 (en) * | 2004-01-15 | 2012-01-17 | Mount Sinai School Of Medicine | Methods and compositions for imaging |
DK2049560T3 (en) * | 2006-07-13 | 2013-07-29 | Novozymes Biopharma Dk As | Process for the preparation of particles of proteinaceous material |
KR100817024B1 (en) * | 2006-11-09 | 2008-03-26 | 재단법인 목암생명공학연구소 | Composite for specifically transporting a nucleic acid or a drug to liver and pharmaceutical composition comprising the same |
-
2009
- 2009-12-11 ES ES200931158A patent/ES2362062B1/en not_active Withdrawn - After Issue
Also Published As
Publication number | Publication date |
---|---|
ES2362062A1 (en) | 2011-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2010329805B2 (en) | New conjugates and compositions for immunotherapy and anti-tumoral treatment | |
CY1123404T1 (en) | ANTI-GIRT ANTIBODIES | |
LTPA2017015I1 (en) | Apoptosis-causing agents for the treatment of cancer and immune and autoimmune diseases | |
GT201200258A (en) | COMPOSITIONS OF ANTI-FACTOR ANTI-FACTOR OF NERVOUS GROWTH (NGF) | |
IN2012DN02736A (en) | ||
MX2018009945A (en) | Novel compositions and methods for the treatment of immune related diseases. | |
DK2459216T3 (en) | IMMUNOGENIC COMPOSITIONS INCLUDING TLR ACTIVITY MODULATORS | |
BR112013032717A2 (en) | glucagon / glp-1 receptor coagonists | |
UY35682A (en) | ANTI-ACTIVINE ANTIBODIES A AND USES OF THE SAME | |
MX2011010977A (en) | Combination immunotherapy compositions against cancer and methods. | |
CL2012001950A1 (en) | Use of a probiotic bacterial strain in the manufacture of a medicament or nutritional composition in humans or animals to alter sleep patterns | |
CO6400149A2 (en) | MYTHATIN LINK PROTEINS | |
EA201101530A1 (en) | IMMUNONANOTHERAPY, PROVIDING TH1-DISPERSED RESPONSE | |
TW201129382A (en) | Antibody formulation and therapeutic regimens | |
TW200637614A (en) | Bendamustine pharmaceutical compositions | |
MX345535B (en) | Partially saturated tricyclic compounds and methods of making and using same. | |
MX2021000715A (en) | Compositions and methods for treating metabolic disorders. | |
BR112012016853A2 (en) | "pharmaceutical compositions for oral administration of insulin peptides". | |
AR091422A1 (en) | PEPTIDIC ANALOGS OF EXENDINA 4 | |
MX2014008705A (en) | Tricyclic sulfone compounds and methods of making and using same. | |
UA102432C2 (en) | Neuropeptide y-cytotoxic conjugates | |
MX2015005732A (en) | Tricyclic compounds and methods of making and using same. | |
MX2013010367A (en) | Compositions and methods for the therapy and diagnosis of influenza. | |
BR112015010639A2 (en) | lactobacillus rhamnosus to reduce body fat accumulation | |
CR20170470A (en) | TREATMENT OF PATIENTS WITH MELLITUS DIABETES TYPE 2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC2A | Transfer of patent | ||
FG2A | Definitive protection |
Ref document number: 2362062 Country of ref document: ES Kind code of ref document: B1 Effective date: 20120509 |
|
FA2A | Application withdrawn |
Effective date: 20121107 |